Elevance Health Inc.
NYSE:ELVMedical - Healthcare Plans
-$3.45 today
- Market cap
- $86.60B
- Beta
- 0.68
- P/E (TTM)
- 16.3
- EPS (TTM)
- $23.78
- Dividend yield
- 1.77%
Volume 1.91M
Average 1.68M
ELV Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Elevance Health Inc.NYSE: ELV
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation dips below year-ago levels
Q3 FY2026 stock-based compensation of $80M fell 4.8% year over year, behind the +10.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 6.7% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.
Context
- Stock-based compensation amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -4.8% toward the trailing-twelve-month pace of +10.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 276M USD
- Year-over-year change
- +44.5%
- 4-year CAGR
- +2.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 276M | +44.5% |
| FY2024 | 2024-12-31 | 191M | -33.9% |
| FY2023 | 2023-12-31 | 289M | +9.5% |
| FY2022 | 2022-12-31 | 264M | +3.5% |
| FY2021 | 2021-12-31 | 255M | — |
Stock-Based Compensation vs competitors
How ELV compares with its peers on the latest reported figures
- ELV's LTM Sep 2026 stock-based compensation of $240M is the 3rd largest of the 9 companies compared; the peer median is $141.5M.
- Its year-over-year change of +10.6% is the 2nd highest of 8, against a peer median of -6.5%.
- Stock-based compensation amounts to 0.1% of revenue for ELV, versus a peer median of 0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.02B | +3.8% | +1.6% | 0.2% | |
| LTM Jun 2026 | $316M | -40.6% | +6.2% | 0.1% | |
| LTM Sep 2026 | $240M | +10.6% | +1.5% | 0.1% | |
| LTM Sep 2026 | $231M | -6.5% | +3.7% | 0.1% | |
| LTM Jun 2026 | $178M | +2.3% | -4.5% | 0.1% | |
| LTM Sep 2026 | $105M | +133.3% | -23.0% | 0.2% | |
| LTM Jun 2026 | $75.19M | -27.9% | -7.9% | 0.5% | |
| LTM Mar 2026 | $58.91M | -12.7% | -8.8% | 1.4% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ELV) | $141.5M | -6.5% | -4.5% | 0.2% | |
Competitors are the stored peer set for ELV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 6.1B | 6.02B | 5.99B | 5.97B | 5.66B |
| Depreciation & Amortization | 1.3B | 1.68B | 1.75B | 1.39B | 1.55B |
| Deferred Income Tax | 173M | (76M) | (602M) | (374M) | (279M) |
| Stock-Based Compensation | 255M | 264M | 289M | 191M | 276M |
| Change in Working Capital | 784M | 253M | (535M) | (1.72B) | (3.28B) |
| Accounts Receivables | (2.14B) | (2.51B) | (1.76B) | (683M) | (2.53B) |
| Inventory | 2.14B | 2.51B | 0 | 0 | 0 |
| Accounts Payables | 719M | 252M | 1.64B | (272M) | (720M) |
| Other Working Capital | 65M | 1M | (413M) | (764M) | (31M) |
| Other Non-Cash Items | (245M) | 264M | 1.18B | 346M | 363M |
| Operating Cash Flow | 8.36B | 8.4B | 8.06B | 5.81B | 4.29B |
| Capital Expenditures | (1.09B) | (1.15B) | (1.3B) | (1.26B) | (1.12B) |
| Acquisitions (Net) | (3.48B) | (649M) | (1.55B) | (4.45B) | 88M |
| Purchases of Investments | (18.67B) | (24.95B) | (16.24B) | (17.99B) | (15.03B) |
| Sales of Investments | 14.61B | 22.61B | 13.54B | 18.57B | 15.1B |
| Other Investing Activities | (1.02B) | (421M) | (24M) | (51M) | (385M) |
| Investing Cash Flow | (9.64B) | (4.56B) | (5.57B) | (5.17B) | (1.34B) |
| Debt Repayment | 2.34B | 1.8B | 739M | 5.56B | 2.33B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (1.9B) | (2.32B) | (2.68B) | (2.9B) | (2.61B) |
| Dividends Paid | (1.1B) | (1.23B) | (1.4B) | (1.51B) | (1.53B) |
| Other Financing Activities | 1.08B | 432M | (17M) | 39M | 69M |
| Financing Cash Flow | 423M | (1.32B) | (3.35B) | 1.19B | (1.74B) |
| Effect of Forex Changes | (10M) | (14M) | (1M) | (72M) | (5M) |
| Net Change in Cash | (861M) | 2.51B | (861M) | 1.76B | 1.2B |
| Free Cash Flow | 7.28B | 7.25B | 6.77B | 4.55B | 3.17B |
Elevance Health Inc.
NYSE:ELV
Intrinsic Alpha fair value
Locked
Current Price
$400.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.